CD22 and COVID-19: Specifically, in the COVID-19 patient’s B cells, we detected a substantial increase in the expression of CD52, CD74, CD22 and CD79B and a decrease in CXCR4, CD69, INFGR1, PTPRC and LAMP1 transcripts with respect to control-derived B cells (Figure 2C,D).